Humanized anti-CLL-1 antibodies
Provided herein are humanized antibodies specific for CLL-1.
1. An antibody that binds CLL-1, the antibody comprising a variable light chain comprising SEQ ID NO: 21 followed by further framework sequence SEQ ID NO: 22; and a variable heavy chain comprising SEQ ID NO: 23 followed by further framework sequence SEQ ID NO: 24.
2. The antibody of claim 1 , wherein the variable light chain comprises SEQ ID NO: 2, and the variable heavy chain comprises SEQ ID NO:8.
3. The antibody of claim 1 , wherein the variable light chain comprises SEQ ID NO: 3, and the variable heavy chain comprises SEQ ID NO:8.
4. The antibody of claim 1 , wherein the variable light chain comprises SEQ ID NO:4, and the variable heavy chain comprises SEQ ID NO:8.
5. The antibody of claim 1 , wherein the variable light chain comprises SEQ ID NO:5, and the variable heavy chain comprises SEQ ID NO:8.
6. The antibody of claim 1 , wherein the antibody comprises an scFv.
7. The antibody of claim 1 , wherein the antibody is a bi-specific antibody comprising a first arm that binds CLL-1 and a second arm that binds a second target antigen selected from the group consisting of CD33, CD123, IL1Rap, GPR114, and CD3 antigen on T cells.
8. The antibody of claim 1 , linked to a cytotoxic agent.
9. The antibody of claim 8 , wherein the cytotoxic agent is a benzodiazepine.
10. The antibody of claim 9 , wherein the benzodiazepine is selected from a pyrrolo benzodiazepine, an indolino benzodiazepine and an isoquinolidinobenzodiazepine, or a hetero dimer or homo dimer thereof.
11. The antibody of claim 1 , further comprising a human constant region selected from IgG1, IgG2, IgG3 and IgG4.
12. The antibody of claim 1 , which is a constant region cysteine-substituted antibody.